RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Pier Luigi Luigi ZinzaniThomas RodgersDario MarinoMaurizio FrezzatoAnna Maria BarbuiClaudia CastellinoErika MeliNathan H FowlerGilles Andre SallesBruce A FeinbergNuwan C KurukulasuriyaSascha TillmannsStephan ParcheDebarshi DeyGünter Fingerle-RowsonSumeet AmbarkhaneMark WinderlichGrzegorz S NowakowskiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
RE-MIND enabled the estimation of the additional treatment effect achieved by combining tafasitamab with lenalidomide in patients with R/R DLBCL.